The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib
Abstract
The regular use of various nonsteroidal anti‐inflammatory drugs (NSAIDs) was shown to decrease the incidence of colorectal cancer. This effect is thought to be caused predominantly by inhibition of cyclooxygenase‐2 (COX‐2) and, subsequently, prostaglandin synthesis. However, recent studies have suggested that COX‐independent pathways may contribute considerably to these antiproliferative effects. To evaluate the involvement of COX‐dependent and COX‐independent mechanisms further, we assessed the effects of celecoxib (selective COX‐2 inhibitor) and SC560 (selective COX‐1 inhibitor) on cell survival, cell cycle distribution, and apoptosis in three colon cancer cell lines, which differ in their expression of COX‐2. Both drugs induced a G0/G1 phase block and reduced cell survival independent of whether or not the cells expressed COX‐2. Celecoxib was more potent than SC560. The G0/G1 block caused by celecoxib could be attributed to a decreased expression of cyclin A, cyclin B1, and cyclin‐dependent kinase‐1 and an increased expression of the cell cycle inhibitory proteins p21 Waf1 and p27 Kip1 . In addition, celecoxib, but not SC560, induced apoptosis, which was also independent of the COX‐2 expression of the cells. In vivo , celecoxib as well as SC560 reduced the proliferation of HCT‐15 (COX‐2 deficient) colon cancer xenografts in nude mice, but both substances had no significant effect on HT‐29 tumors, which express COX‐2 constitutively. Thus, our in vitro and in vivo data indicate that the antitumor effects of celecoxib probably are mediated through COX‐2 independent mechanisms and are not restricted to COX‐2 over‐expressing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
Features of apoptotic cells measured by flow cytometry
Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M. A., Lassota, P., & Traganos, F. (1992) · Cytometry · doi:10.1002/cyto.990130802 · Cited by 1,883
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., & Hla, T. (1995) · PubMed · Cited by 1,126
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,114
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
D-type cyclin-dependent kinase activity in mammalian cells.
Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., & Kato, J. Y. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2066 · Cited by 1,064
Formation and Activation of a Cyclin E-cdk2 Complex During the G 1 Phase of the Human Cell Cycle
Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S., Nishimoto, T., Morgan, D. O., Franza, B. R., & Roberts, J. M. (1992) · Science · doi:10.1126/science.1388288 · Cited by 1,043
Resnitzky, D., Gossen, M., Bujard, H., & Reed, S. I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1669-1679.1994 · Cited by 965
Pines, J., & Hunter, T. (1989) · Cell · doi:10.1016/0092-8674(89)90936-7 · Cited by 908
Association of human cyclin E with a periodic G1-S phase protein kinase
Dulic, V, Lees, E., & Reed, S. (1992) · Science · doi:10.1126/science.1329201 · Cited by 881
Pharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
Meyerson, M., & Harlow, E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2077 · Cited by 794
Cyclin-Dependent Regulation of G 1 in Mammalian Fibroblasts
Ohtsubo, M., & Roberts, J. M. (1993) · Science · doi:10.1126/science.8384376 · Cited by 756
Niculescu, A. B., Chen, X., Smeets, M., Hengst, L., Prives, C., & Reed, S. I. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.629 · Cited by 724
Sulindac causes regression of rectal polyps in familial adenomatous polyposis
Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., & Attali, P. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90519-q · Cited by 719
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., & DuBois, R. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119400 · Cited by 712
Hsu, A.-L., Ching, T.-T., Wang, D.-S., Song, X., Rangnekar, V. M., & Chen, C.-S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.11397 · Cited by 671
Resnitzky, D., Gossen, M., Bujard, H., & Reed, S. I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1669 · Cited by 664
Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., & Rigas, B. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00181-5 · Cited by 608
Fang, F., & Newport, J. W. (1991) · Cell · doi:10.1016/0092-8674(91)90117-h · Cited by 483
The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells
Riabowol, K., Draetta, G., Brizuela, L., Vandre, D., & Beach, D. (1989) · Cell · doi:10.1016/0092-8674(89)90914-8 · Cited by 425
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor
Davies, N. M., McLachlan, A. J., Day, R. O., & Williams, K. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038030-00003 · Cited by 424
Colorectal Cancer and Nonsteroidal Anti-inflammatory Drugs
Smalley, W. E., & DuBois, R. N. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60067-8 · Cited by 356
Nuclear Accumulation of p21 Cip1 at the Onset of Mitosis: a Role at the G 2 /M-Phase Transition
Dulić, V., Stein, G. H., Far, D. F., & Reed, S. I. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.546 · Cited by 353
Zhang, X., Morham, S. G., Langenbach, R., & Young, D. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.4.451 · Cited by 273
Smalley, W., Ray, W. A., Daugherty, J., & Griffin, M. R. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.2.161 · Cited by 264
Stark, L. A., Din, F. V. N., Zwacka, R. M., & Dunlop, M. G. (2001) · The FASEB Journal · doi:10.1096/fj.00-0529fje · Cited by 191
Niculescu, A. B., Chen, X., Smeets, M. F. M. A., Hengst, L., Prives, C. L., & Reed, S. I. (1998) · Molecular and Cellular Biology · Cited by 177
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
Wechter, W. J., Leipold, D. D., Murray, E. D., Quiggle, D. D., McCracken, J. D., Barrios, R. J., & Greenberg, N. M. (2000) · PubMed · Cited by 164
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB
Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C., Bräutigam, L., Grösch, S., & Geißlinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.00-0716fje · Cited by 153
Self-citationSoh, J. W., Mao, Y. K., Kim, M., Pamukcu, R., Li, H., Piazza, G. A., Thompson, W. J., & Weinstein, I. B. (2000) · PubMed · Cited by 134
Bak, A., McKnight, W., Li, P., Soldato, P. D., Calignano, A., Cirino, G., & Wallace, J. L. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00191-x · Cited by 110
Marra, D. E., Simoncini, T., & Liao, J. K. (2000) · Circulation · doi:10.1161/01.cir.102.17.2124 · Cited by 110
van Stolk, R. U., Stoner, G. D., Hayton, W. L., Chan, K. K., DeYoung, B. R., Kresty, L. A., Kemmenoe, B. H., Elson, P. J., Rybicki, L. A., Church, J. M., et al. (2000) · PubMed · Cited by 105
Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous Polyposis
Stoner, G. D., Budd, G. T., Ganapathi, R., Young, B. D., Kresty, L. A., Nitert, M. D., Fryer, B., Church, J. M., Provencher, K., Pamukcu, R., et al. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4149-3_5 · Cited by 104
Wechter, W. J., Kantoci, D., Murray, E. D., Quiggle, D. D., Leipold, D. D., Gibson, K. M., & McCracken, J. D. (1997) · PubMed · Cited by 98
Rice, P. L., Goldberg, R. J., Ray, E. C., Driggers, L. J., & Ahnen, D. J. (2001) · PubMed · Cited by 82
Toledo, S. D., Azzam, E. I., Keng, P. C., Laffrenier, S., & Little, J. B. (1998) · PubMed · Cited by 74
Treatment and survival study in the C57BL/6J-APCMin/+ (Min) mouse with R-flurbiprofen
Wechter, W. J., Murray, E., Kantoci, D., Quiggle, D. D., Leipold, D. D., Gibson, K. M., & McCracken, J. D. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00645-1 · Cited by 63
CDC2 is down-regulated by ionizing radiation in a p53-dependent manner.
Azzam, E. I., Toledo, S. D., Pykett, M. J., Nagasawa, H. T., & Little, J. B. (1997) · PubMed · Cited by 63
Damiens, E. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_19 · Cited by 10
Cited by
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
The Wnt signaling pathway in cancer
Duchartre, Y., Kim, Y.-M., & Kahn, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.005 · Cited by 548
Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Takahashi-Yanaga, F., & Kahn, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2943 · Cited by 499
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
Chun, K.-S., & Surh, Y.-J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.031 · Cited by 402
Metadata
- Authors
- Grösch, S., Tegeder, I., Niederberger, E., Bräutigam, L., & Geisslinger, G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-10-15
- Volume
- 15
- Issue
- 14
- Pages
- 1-22
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2105372476
- Cited by
- 501
- References
- 47
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.